Current Status and Progress on Diagnosis and Treatment of Malignant Peritoneal Mesothelioma
-
摘要:
恶性腹膜间皮瘤是一种临床罕见，与石棉暴露密切相关的高侵袭性肿瘤。由于前期石棉材料的广泛应用，目前发病率呈明显上升趋势。该病起病隐匿，临床确诊时多为晚期，预后较差，中位生存期仅为12月。恶性腹膜间皮瘤治疗方法主要是肿瘤细胞减灭术联合腹腔热灌注化疗，目前多项免疫及分子靶向治疗正在研究中。本文就恶性腹膜间皮瘤的诊治现状作一综述，以期提高对该病的认识，进而为恶性腹膜间皮瘤的诊治提供参考。
Abstract:Malignant peritoneal mesothelioma(MPM) is a rare and aggressive tumor and highly associated with asbestos exposure. Due to the wide application of asbestos materials in the early stage, the incidence of MPM is increasing now. The symptoms of MPM are atypical, so most of patients are in the late stage when diagnosed. And the prognosis is so poor that the median survival time is only 12 months. Now the main treatment of MPM is CRS-HIPEC, at the same time, a number of immune and targeted treatments are under study. This article reviews the current status of treatment on MPM, aiming to improve the understandings of this disease and provide a reference for the clinical diagnosis and treatment.
-
Key words:
- Malignant peritoneal mesothelioma /
- Diagnosis /
- Therapy
-
Competing interests: The authors declare that they have no competing interests.作者贡献李娜：文献搜集、整理及论文撰写陈忠坚：文章审校毛伟敏：提出选题、确定文章架构及文章审校
-
[1] Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review[J]. Transl Lung Cancer Res, 2018, 7(5): 537-542. http://www.ncbi.nlm.nih.gov/pubmed/28706904
[2] 廖子君, 张彦兵, 郑琪, 等.一例恶性腹膜间皮瘤误诊为结肠癌报道及文献复习[J].中华结直肠疾病电子杂志, 2019, 8(4): 403-407. http://www.cnki.com.cn/Article/CJFDTotal-ZHZC201904015.htm Liao ZJ, Zhang YB, Zheng Q, et al. A case of malignant peritoneal mesothelioma was misdiagnosed as colon cancer and the literature review[J]. Zhonghua Jie Zhi Chang Ji Bing Dian Zi Za Zhi, 2019, 8(4): 403-407. http://www.cnki.com.cn/Article/CJFDTotal-ZHZC201904015.htm
[3] Boussios S, Moschetta M, Karathanasi A, et al. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives[J]. Ann Gastroenterol, 2018, 31(6): 659-669. http://www.ncbi.nlm.nih.gov/pubmed/30386115
[4] Kato K, Gemba K, Fujimoto N, et al. Fatal pleural mesothelioma in Japan (2003-2008): evaluation of computed tomography findings[J]. Jpn J Radiol, 2016, 34(6): 432-438.
[5] 陈凯燕, 郭振英, 苏丹, 等.恶性间皮瘤在中国的发病及诊治现状分析[J].中华胸心血管外科杂志, 2017, 33(7): 443-446. http://d.wanfangdata.com.cn/periodical/zhxxxgwk201707019 Chen KY, Guo ZY, Su D, et al. Epidemiology and clinical diagnosis and treatment of malignant mesothelioma in China[J]. Zhonghua Xiong Xin Xue Guan Wai Ke Za Zhi, 2017, 33(7): 443-446. http://d.wanfangdata.com.cn/periodical/zhxxxgwk201707019
[6] Carbone M, Adusumilli PS, Alexander HR Jr, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy[J]. CA Cancer J Clin, 2019, 69(5): 402-429. doi: 10.3322/caac.21572
[7] Tandon RT, Jimenez-Cortez Y, Taub R, et al. Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases[J]. Arch Pathol Lab Med, 2018, 142(2): 236-242. http://www.onacademic.com/detail/journal_1000040097866810_0458.html
[8] Chapel DB, Churg A, Santoni-Rugiu E, et al. Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group[J]. Lung Cancer, 2019, 127: 69-75. http://www.sciencedirect.com/science/article/pii/S0169500218306718
[9] Hassan R, Morrow B, Thomas A, et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy[J]. Proc Natl Acad Sci U S A, 2019, 116(18): 9008-9013. http://www.researchgate.net/publication/332455699_Inherited_predisposition_to_malignant_mesothelioma_and_overall_survival_following_platinum_chemotherapy
[10] Kittaneh M, Berkelhammer C. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members[J]. J Transl Med, 2018, 16(1): 194. doi: 10.1186/s12967-018-1559-7/fulltext.html
[11] Panou V, Gadiraju M, Wolin A, et al. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma[J]. J Clin Oncol, 2018, 36(28): 2863-2871.
[12] Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review[J]. Ann Transl Med, 2017, 5(11): 236. https://pubmed.ncbi.nlm.nih.gov/28706904/
[13] Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*[J]. Cancer, 2011, 117(9): 1855-1863.
[14] Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2015, 22(5): 1686-1693.
[15] Baratti D, Kusamura S, Cabras AD, et al. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study[J]. Ann Surg Oncol, 2012, 19(5): 1416-1424. doi: 10.1245/s10434-012-2237-2
[16] García-Fadrique A, Mehta A, Mohamed F, et al. Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review[J]. J Gastrointest Oncol, 2017, 8(5): 915-924. http://www.ncbi.nlm.nih.gov/pubmed/29184697
[17] Sugarbaker PH. Update on the management of malignant peritoneal mesothelioma[J]. Transl Lung Cancer Res, 2018, 7(5): 599-608. http://www.onacademic.com/detail/journal_1000041678856999_f502.html
[18] Lemoine L, Sugarbaker P, Van der Speeten K. Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma[J]. Int J Hyperthermia, 2017, 33(5): 582-592.
[19] Enomoto LM, Shen P, Levine EA, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: patient selection and special considerations[J]. Cancer Manag Res, 2019, 11: 4231-4241. http://www.researchgate.net/publication/332908368_Cytoreductive_surgery_with_hyperthermic_intraperitoneal_chemotherapy_for_peritoneal_mesothelioma_patient_selection_and_special_considerations
[20] 陈小兵, 苗成利, 罗成华.恶性腹膜间皮瘤治疗及预后研究进展[J].中国微创外科杂志, 2019, 19(7): 630-633. http://www.cnki.com.cn/Article/CJFDTotal-ZWWK201907015.htm Chen XB, Miao CL, Luo CH. Advances in treatment and prognosis of malignant peritoneal mesothelioma[J]. Zhongguo Wei Chuang Wai Ke Za Zhi, 2019, 19(7): 630-633. http://www.cnki.com.cn/Article/CJFDTotal-ZWWK201907015.htm
[21] Alexander HR Jr, Li CY, Kennedy TJ. Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma[J]. Ann Surg Oncol, 2018, 25(8): 2159-2164. doi: 10.1245/s10434-018-6337-5
[22] Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma[J]. Ann Surg Oncol, 2007, 14(1): 41-49.
[23] Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase Ⅱ trial[J]. J Clin Oncol, 2008, 26(21): 3567-3572. http://www.ncbi.nlm.nih.gov/pubmed/18640937
[24] Schaub NP, Alimchandani M, Quezado M, et al. A novel nomogram for peritoneal mesothelioma predicts survival[J]. Ann Surg Oncol, 2013, 20(2): 555-561. doi: 10.1245/s10434-012-2651-5
[25] Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival[J]. Eur J Surg Oncol, 2017, 43(7): 1228-1235. http://www.sciencedirect.com/science/article/pii/S0748798317300598
[26] Chia PL, Scott AM, John T. Epidermal growth factor receptor (EGFR)-targeted therapies in mesothelioma[J]. Expert Opin Drug Deliv, 2019, 16(4): 441-451. http://www.onacademic.com/detail/journal_1000042291281399_8c5d.html
[27] Scherpereel A, Wallyn F, Albelda SM, et al. Novel therapies for malignant pleural mesothelioma[J]. Lancet Oncol, 2018, 19(3): e161-e172. http://www.sciencedirect.com/science/article/pii/S1470204518301001
[28] Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase Ⅱ Results From the Randomized, Placebo-Controlled LUME-Meso Trial[J]. J Clin Oncol, 2017, 35(31): 3591-3600.
[29] Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2016, 387(10026): 1405-1414. http://www.sciencedirect.com/science/article/pii/S0140673615012386
[30] Dolly SO, Migali C, Tunariu N, et al. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy[J]. ESMO Open, 2017, 2(1): e000101. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519796/
[31] Kim JE, Kim D, Hong YS, et al. Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS[J]. Transl Oncol, 2018, 11(2): 268-274. http://www.sciencedirect.com/science/article/pii/S1936523317304291
[32] Hung YP, Dong F, Watkins JC, et al. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma[J]. JAMA Oncol, 2018, 4(2): 235-238. http://www.ncbi.nlm.nih.gov/pubmed/28910456
[33] 宁岩, 王丹云.恶性胸膜间皮瘤免疫检查点抑制剂临床治疗进展[J].中华胸部外科电子杂志, 2018, 5(4): 254-260. http://www.cnki.com.cn/Article/CJFDTotal-XBWK201804011.htm Ning Y, Wang DY. Progress in clinical researches of immunotherapy for malignant pleural mesothelioma in regards of immunoligical checkpoint inhibitor[J]. Zhonghua Xiong Bu Wai Ke Dian Zi Za Zhi, 2018, 5(4): 254-260. http://www.cnki.com.cn/Article/CJFDTotal-XBWK201804011.htm
[34] Maio M, Scherpereel A, Calabrò L, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial[J]. Lancet Oncol, 2017, 18(9): 1261-1273.
[35] Wei SC, Levine JH, Cogdill AP, et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade[J]. Cell, 2017, 170(6): 1120-1133. http://www.sciencedirect.com/science/article/pii/S0092867417308310
[36] Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study[J]. Lancet Respir Med, 2018, 6(6): 451-460. http://www.sciencedirect.com/science/article/pii/S2213260018301516
[37] Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial[J]. Lancet Respir Med, 2019, 7(3): 260-270. http://www.sciencedirect.com/science/article/pii/S221326001830420X
下载: 计量
- 文章访问数: 3710
- HTML全文浏览量: 522
- PDF下载量: 1455
